BMS’ deucravacitinib tops Otezla in two psoriasis studies
Deucravacitinib demonstrated superior skin clearance compared with Otezla
Read More
Tag: deucravacitinib
Bristol Myers Squibb’s psoriasis med hits the mark in phase III
Deucravacitinib demonstrated superiority to placebo and Otezla in phase III
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
